4/A: Dexcom Director Amends SEC Filing to Correct Restricted Stock Unit Grant

Dexcom Director Renee D. Gala filed an amended Form 4 to correct a previously misreported grant of 1,161 unvested restricted stock units.

Summary

• Dexcom Director Renee D. Gala filed a Form 4/A, an amendment to a Statement of Changes in Beneficial Ownership, to correct a calculation error in a previous filing.
• The original Form 4, filed on May 12, 2025, misreported the number of unvested restricted stock units (RSUs) granted to Ms. Gala on May 8, 2025.
• This amendment correctly reports the acquisition of 1,161 unvested restricted stock units on May 8, 2025, at a price of $0.
• Following this transaction, Ms. Gala beneficially owns a total of 6,881 unvested restricted stock units.
• Of the 6,881 total, 5,720 RSUs were granted on March 6, 2025, and are set to vest through March 6, 2028.
• The 1,161 RSUs granted on May 8, 2025, will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: The document is an administrative correction of a previous filing, indicating a neutral impact. While an initial error occurred, the prompt correction demonstrates regulatory compliance.

Positives

• The grant of 1,161 unvested restricted stock units to Director Renee D. Gala aligns her interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The company demonstrated transparency and adherence to regulatory requirements by promptly correcting the misreported information through an amended filing.

Negatives

• The initial misreporting of the number of restricted stock units indicates an administrative or calculation error in the original filing.

Risks

• No specific risks are mentioned in the document beyond the administrative error in the initial filing, which has now been corrected.

Future Outlook

The 1,161 unvested restricted stock units granted on May 8, 2025, are scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Additionally, 5,720 unvested restricted stock units granted on March 6, 2025, are set to vest through March 6, 2028.

Industry Context

This filing is a routine regulatory disclosure of insider ownership changes, specifically an amendment to correct a previous filing. It does not provide information related to broader industry trends or competitive landscape beyond the specific company's executive compensation practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides accurate information regarding a director's equity compensation, ensuring transparency in executive incentives and beneficial ownership.
• Regulatory Authorities: Demonstrates compliance with SEC reporting requirements by correcting an error in a timely manner.

Next Steps

• Vesting of 1,161 restricted stock units on the earlier of May 8, 2026, or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
• Continued vesting of 5,720 restricted stock units through March 6, 2028.

Key Dates

Keywords

Dexcom, DXCM, SEC Filing, Form 4/A, Beneficial Ownership, Restricted Stock Units, RSU, Insider Transaction, Corporate Governance, Director Compensation